Moneycontrol PRO
HomeAuthorViswanath pilla

Viswanath Pilla

Senior Assistant Editor

Moneycontrol News

Explained | Why kids need separate trials for COVID-19 vaccine, how are trials conducted, and enrollment challenges

BUSINESS

Explained | Why kids need separate trials for COVID-19 vaccine, how are trials conducted, and enrollment challenges

While US firm Moderna has started testing its vaccine on children, Pfizer and AstraZeneca-Oxford University are planning to follow suit. In India, Bharat Biotech is seeking permission to test its vaccine, Covaxin, on children aged between 5 and 18 years.

COVID-19 vaccines: Public health experts urge government to release details of adverse event data

BUSINESS

COVID-19 vaccines: Public health experts urge government to release details of adverse event data

Twenty-nine experts from various fields have written a letter noting that the government had stopped sharing any details on Adverse Events Following Immunisation (AEFI) after February 26, 2021. The experts have sought details from the government on the findings of all completed AEFI investigations. The letter said that at least 65 deaths have occurred following vaccination for Covid-19 since the campaign began on January 16. However, the National AEFI Committee’s reports on only two of those deaths have been made public.

Gland Pharma teams up with RDIF to manufacture 252 mn doses of Russia's Sputnik V COVID vaccine

BUSINESS

Gland Pharma teams up with RDIF to manufacture 252 mn doses of Russia's Sputnik V COVID vaccine

Under the terms of the agreement, Gland Pharma said it will first undertake technology transfer of the drug substance to its manufacturing facilities. After successful technology transfer, Gland Pharma will then undertake manufacturing of drug substance and drug product filling into vials under aseptic conditions.

Will White House backing hoist Biological E to the big league of COVID-19 vaccine makers?

BUSINESS

Will White House backing hoist Biological E to the big league of COVID-19 vaccine makers?

After being overshadowed by the Serum Institute of India and Bharat BioTech, India’s first private vaccine maker has sprung into action with US funding that will help it produce 1 billion doses of COVID-19 vaccines by the end of next year.

No evidence of link between COVID-19 vaccine, blood clots: AstraZeneca

BUSINESS

No evidence of link between COVID-19 vaccine, blood clots: AstraZeneca

AstraZeneca said there were no confirmed issues related to any batch of its vaccine used across Europe, or the rest of the world.

Pharma wrap | AstraZeneca-Oxford vaccine on hold in Europe, what does it mean for India?

BUSINESS

Pharma wrap | AstraZeneca-Oxford vaccine on hold in Europe, what does it mean for India?

The Indian government has said it is reviewing the situation. The vaccine hasn't been linked to any deaths in the country.

Novavax COVID-19 vaccine found to be 96.4% effective in final analysis of UK Phase-3 study

BUSINESS

Novavax COVID-19 vaccine found to be 96.4% effective in final analysis of UK Phase-3 study

The vaccine would be manufactured at eight locations including the Serum Institute of India, with which Novavax has an agreement to produce around 2 billion doses a year.

Input material shortages may hit COVID-19 vaccine manufacturing, says report

BUSINESS

Input material shortages may hit COVID-19 vaccine manufacturing, says report

The shortages may emerge though several suppliers expanded their capacity by 50 percent in 2020. Many are also planning to expand production by another 50 percent in 2021.

DCGI drops 'clinical trial mode' condition for Bharat Biotech's Covaxin

BUSINESS

DCGI drops 'clinical trial mode' condition for Bharat Biotech's Covaxin

Currently, those receiving Bharat Biotech’s Covaxin are asked to sign a consent form before being vaccinated.

HMD bags order to supply 265 million auto disposable syringes from government

BUSINESS

HMD bags order to supply 265 million auto disposable syringes from government

The government has issued tenders to procure 350 million pieces of AD syringes to use in COVID-19 vaccination.

Covaxin or Covishield? What you should know about each COVID-19 vaccine

BUSINESS

Covaxin or Covishield? What you should know about each COVID-19 vaccine

Granted people in India cannot choose between Serum Institute of India’s (SII) Covishield and Bharat Biotech's Covaxin but here is a guide to help you understand some of the important facts about each vaccine.

Max Healthcare raises Rs 1,200 through QIP, sells shares at Rs 195.4 apiece

BUSINESS

Max Healthcare raises Rs 1,200 through QIP, sells shares at Rs 195.4 apiece

Max Healthcare proposes to utilise the net proceeds for meeting the capital expenditure and working capital requirements, including expansion of capacity, and increasing stake in existing and future subsidiaries.

World may see 18 percent shortfall in supply of COVID-19 vaccines in 2021: Report

BUSINESS

World may see 18 percent shortfall in supply of COVID-19 vaccines in 2021: Report

Airfinity pegs the global demand for COVID-19 vaccines in 2021 at 11.5 billion doses, while the forecasted production is estimated to be 9.5 billion doses.

Brazil's drug regulator Anvisa inspects Bharat Biotech's facility, may give nod to Covaxin soon

BUSINESS

Brazil's drug regulator Anvisa inspects Bharat Biotech's facility, may give nod to Covaxin soon

Brazil is the first country to sign a definitive supply agreement with Bharat Biotech to procure 20 million doses of Covaxin on February 26. The deliveries are expected to begin during Q2 and Q3 of 2021.

How doctor-turned-entrepreneur Chaitra Harsha wants to build India's next big CRO from Mysore

BUSINESS

How doctor-turned-entrepreneur Chaitra Harsha wants to build India's next big CRO from Mysore

Dr Chaitra Harsha has dabbled in setting up dental clinics, a medical tourism venture, offered consulting services in the area of bioinformatics, among others.

Why pharma sales function has too few women?

BUSINESS

Why pharma sales function has too few women?

Though the marketing and sales division has traditionally given pharma sector its leaders, women are still a small percentage here. A pharma association data says that while the average percentage of women in most sectors in India is between 15- 35%, in the pharma industry, it is 10–15%.

Pharma wrap: Has the reboot helped PM's Jan Aushadhi scheme to sell affordable medicines?

BUSINESS

Pharma wrap: Has the reboot helped PM's Jan Aushadhi scheme to sell affordable medicines?

Plagued by supply chain and quality issues and corruption, the scheme was revamped as Pradhan Mantri Bhartiya Janaushadhi Pariyojana in 2015-16. The store count has increased from 5,140 in FY 2019 to 7,500 in FY21 and turnover has jumped from Rs 315 crore to Rs 600 crore.

US export curbs on COVID-19 vaccine ingredients limiting efforts to scale up production: Adar Poonawalla

BUSINESS

US export curbs on COVID-19 vaccine ingredients limiting efforts to scale up production: Adar Poonawalla

The US has invoked the Defense Act, which has a sub- clause that prevents the export of critical raw materials required for local vaccine manufacturers.

EXPLAINED | Covaxin shows 81% efficacy, here's how it stacks up against Covishield

BUSINESS

EXPLAINED | Covaxin shows 81% efficacy, here's how it stacks up against Covishield

Here is a comparison between the two COVID-19 vaccines – Covishield and Covaxin - approved in India.

81% interim efficacy data boosts Bharat Biotech's hopes of Covaxin exports

BUSINESS

81% interim efficacy data boosts Bharat Biotech's hopes of Covaxin exports

Bharat Biotech said another interim analysis and a final one is expected in the weeks ahead, which will give a more robust picture of Covaxin's efficacy.

Govt steps up COVID-19 vaccination pace, to allow more private hospitals to administer vaccines

BUSINESS

Govt steps up COVID-19 vaccination pace, to allow more private hospitals to administer vaccines

The government's latest direction to states, will significantly increase the capacity. India has a total of 43,486 private hospitals. On an average, India is inoculating about 5-6 lakh people a day, way short of the government's target of 13 lakh.

COVID-19 vaccination | Private hospitals ramp up capacities to fast-track inoculation

BUSINESS

COVID-19 vaccination | Private hospitals ramp up capacities to fast-track inoculation

It is estimated that 20,000 private facilities will be available as COVID-19 vaccination centre.

About 92% people who tried using Co-WIN portal faced difficulties: Survey

BUSINESS

About 92% people who tried using Co-WIN portal faced difficulties: Survey

In a separate survey Local Circles said it also found that the Prime Minister Narendra Modi taking the jab, helped to reduce the vaccine hesitancy to 36 percent.

CoWIN registration for 18-44 age group open, but unable to secure a spot? Here's why and other questions answered

INDIA

CoWIN registration for 18-44 age group open, but unable to secure a spot? Here's why and other questions answered

Here's a quick guide on the CoWIN registration process, if you can choose between COVID-19 vaccines and more.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347